The risk of worsening of myasthenia by cardiovascular medication as reflected by reporting frequency

SYNOPSIS This study examines the association between mandatory financial reporting frequency and the accrual anomaly. Based on regulatory changes in reporting frequency requirements in Taiwan, we divide our sample period into three reporting regimes: a semiannual reporting regime from 1982 to 1985, a quarterly reporting regime from 1986 to 1987, and a monthly reporting regime (both quarterly financial reports and monthly revenue disclosure) from 1988 to 1993. We find that although both switches (from the semiannual reporting regime to the quarterly reporting regime and from the quarterly reporting regime to the monthly reporting regime) hasten the dissemination of the information contained in annual accruals into stock prices and reduce annual accrual mispricing, the switch to monthly reporting has a lesser effect. Our results are robust to controlling for risk factors, transaction costs, and potential changes in accrual, cash flow persistence, and sample composition over time. These results imply that more frequent reporting is one possible mechanism to reduce accrual mispricing. JEL Classifications: G14; L51; M41; M48. Data Availability: Data are available from sources identified in the paper.

Download Full-text

Pharmacovigilance assessment of the association between Fournier’s gangrene and other severe genital adverse events with SGLT-2 inhibitors

BMJ Open Diabetes Research & Care ◽

10.1136/bmjdrc-2019-000725 ◽

2019 ◽

Vol 7 (1) ◽

pp. e000725 ◽

Cited By ~ 7

Author(s):

Gian Paolo Fadini ◽

Mayur Sarangdhar ◽

Fabrizio De Ponti ◽

Angelo Avogaro ◽

Emanuel Raschi

Keyword(s):

Reporting System ◽

Immunosuppressive Drugs ◽

Fournier’S Gangrene ◽

Rare Occurrence ◽

Fournier's Gangrene ◽

Glucose Lowering ◽

Sodium Glucose Cotransporter ◽

Definition Of ◽

Reporting Frequency ◽

Design And Methods

ObjectiveSodium glucose cotransporter-2 inhibitors (SGLT2i) exert cardiorenal protection in people with diabetes. By inducing glycosuria, SGLT2i predispose to genital infections. In addition, rare occurrence of Fournier’s gangrene (FG) has been reported. We aimed to investigate such association through the U.S. Food and Drug Administration (FDA) adverse event (AE) reporting system (FAERS).Research design and methodsWe mined the FAERS up to 2018q3 (before FDA warning about SGLT2i-associated FG) to retrieve reports including FG as an AE and SGLT2i as suspect or concomitant drugs, and calculated proportional reporting ratios (PRR).ResultsWe retrieved 47 cases of FG and 17 cases of other severe AEs of the genital area associated with SGLT2i. Patients with FG were ~10 years older than those with other severe genital AEs. Overall, 77% occurred in men. Three patients were concomitantly treated with systemic immunosuppressive drugs. Increased reporting frequency emerged for SGLT2i compared with other drugs, with a PRR ranging from 5 to 10. The disproportional reporting of FG with SGLT2i remained robust and consistently significant when restricting to the period when SGLT2i were available, to reports filed for glucose-lowering medications or for drugs with the diabetes indication, and after refining the definition of FG. FG was disproportionally associated with psoriasis and with the combination of immunosuppressants and SGLT2i.ConclusionsAlthough causality cannot be demonstrated, SGLT2i may predispose to FG and other severe genital AEs. Since the use of SGLT2i is expected to increase significantly, clinicians should be aware of these severe, although rare, AEs and their predisposing factors.

Download Full-text

Relationship between pre-stroke cardiovascular medication use and stroke severity

European Journal of Clinical Pharmacology ◽

10.1007/s00228-015-2001-1 ◽

2015 ◽

Vol 72 (4) ◽

pp. 495-502 ◽

Cited By ~ 2

Author(s):

S. Desmaele ◽

P. Cornu ◽

K. Barbé ◽

R. Brouns ◽

S. Steurbaut ◽

...

Keyword(s):

Medication Use ◽

Stroke Severity ◽

Cardiovascular Medication

Download Full-text

Benefits and pitfalls of cardiovascular medication in seniors

Wiener klinische Wochenschrift ◽

10.1007/s00508-013-0395-2 ◽

2013 ◽

Vol 125 (15-16) ◽

pp. 425-436 ◽

Cited By ~ 8

Author(s):

Hana Matejovska Kubesova ◽

Pavel Weber ◽

Hana Meluzinova ◽

Katarina Bielakova ◽

Jan Matejovsky

Keyword(s):

Cardiovascular Medication

Download Full-text

Cardiovascular medication use after coronary bypass surgery in patients with renal dysfunction: A National Veterans Administration study[1]

Kidney International ◽

10.1016/s0085-2538(15)50905-8 ◽

2005 ◽

Vol 68 (2) ◽

pp. 826-832 ◽

Cited By ~ 20

Author(s):

Eric M. Gibney ◽

Adrianne W. Casebeer ◽

Lynn M. Schooley ◽

Francesca Cunningham ◽

Frederick L. Grover ◽

...

Keyword(s):

Renal Dysfunction ◽

Bypass Surgery ◽

Medication Use ◽

Coronary Bypass ◽

Coronary Bypass Surgery ◽

Veterans Administration ◽

Cardiovascular Medication

Download Full-text